

001568711

IAP20 Recd/PATENTO 17 FEB 2006

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93208

Hidenori URATA, et al.

Appln. No.: Based on PCT/JP2004/012335

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: February 17, 2006

Examiner: Unknown

For: DRUGS CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

IAP20 Receipt No. 10 17 FEB 2006

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP2004/012335


on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: February 17, 2006

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Based on PCT/JP2004/012335
				Confirmation Number	Unknown 1568711
				Filing Date	February 17, 2006
				First Named Inventor	Hidenori URATA
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	Q93208

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	Number ⁴		
	JP	2002-138054	A	05-14-2002	Takeda Chemical Industries, Ltd.
	WO	00/10605	A2	03-02-2000	Senju Pharmaceutical Co., Ltd.
	JP	2001-114699	A	04-24-2001	Santen Pharmaceutical Co., Ltd.
	WO	01/32621	A1	05-10-2001	Wakunaga Pharmaceutical Co., Ltd.
	WO	01/62292	A1	08-30-2001	Suntory Ltd.
	WO	01/53291	A1	07-26-2001	Teijin Ltd.
	WO	01/53272	A1	07-26-2001	Teijin Ltd.
	WO	00/03997	A1	01-27-2000	Teijin Ltd.
	WO	00/05204	A1	02-03-2000	Shionogi & Co., Ltd.
	WO	98/09949	A1	03-12-1998	Nippon Kayaku Co., Ltd.
	WO	98/18794	A1	05-07-1998	The Green Cross Corp.
	WO	00/51640	A1	09-08-2000	Yoshitomi Pharmaceutical Industries, Ltd.
	WO	02/22595	A1	03-21-2002	Toa Eiyo Ltd.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Hidenori URATA, "A II Sansei Kei to sono Yokuseiho, Ketsuatsu", 2002, 9(8), pages 763 to 768	
		Naohisa ODA et al., "Shizen Hassho Tonyobyo Rat (OLETF Rat) no Totaisha Shogai ni Taisuru ACE Sogaizai no Koka", Nichi Naibunpitsu Kaishi, 1997, 73(3), pages 487 to 493	
		Kazuki IZUMI et al., "ACE Sogaiyaku ni yoru Insulin Teikosei Kaizen no Mechanism", Endocrinology & diabetology 2001, 12(4), pages 391 to 397	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.